icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
nLNWQh0dYEHEtFEW